Clinical data | |
---|---|
Trade names | Vermox,[1] Ovex, others |
Other names | MBZ |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682315 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 2–10% |
Protein binding | 95% |
Metabolism | Extensive liver |
Elimination half-life | 3–6 hours |
Excretion | Feces, urine (5–10%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.046.017 |
Chemical and physical data | |
Formula | C16H13N3O3 |
Molar mass | 295.298 g·mol−1 |
3D model (JSmol) | |
Melting point | 288.5 °C (551.3 °F) |
| |
| |
(verify) |
Mebendazole (MBZ), sold under the brand name Vermox among others, is a medication used to treat a number of parasitic worm infestations.[5] This includes ascariasis, pinworm infection, hookworm infections, guinea worm infections, hydatid disease, and giardia, among others.[5] It is taken by mouth.[5]
Mebendazole is usually well tolerated.[5] Common side effects include headache, vomiting, and ringing in the ears.[5] If used at large doses it may cause bone marrow suppression.[5] It is unclear if it is safe in pregnancy.[5][2] Mebendazole is a broad-spectrum antihelminthic agent of the benzimidazole type.[5]
Mebendazole came into use in 1971, after it was developed by Janssen Pharmaceutica in Belgium.[6] It is on the World Health Organization's List of Essential Medicines.[7] Mebendazole is available as a generic medication.[8]